According to a recent Form 4 filing with the U.S. Securities and Exchange Commission (SEC), Julie Rubinstein, President and Chief Operating Officer of biotechnology company Adaptive Biotechnologies (ADPT), and Francis Lo, Chief People Officer, conducted transactions to sell the company’s common stock in March 2026. The filing indicates that the transactions were conducted in accordance with pre-established trading plans or company policies to meet tax obligations, and do not reflect any judgmental action regarding the company’s outlook.
The filing disclosed that Rubinstein sold 179,703 shares of common stock between March 11 and 13, 2026, following the exercise of stock options. Following the sale, Rubinstein’s direct holdings of common stock decreased by 26.1%, leaving her with 507,934 shares directly held.
Meanwhile, Chief People Officer Francis Lo sold a total of 68,667 shares of common stock in two transactions in early March 2026. After the transactions, Lo still directly holds 291,374 shares and indirectly holds 2,500 shares through a spouse’s account. Based on the current stock price, the value of his direct holdings is approximately $4.1 million.
Adaptive Biotechnologies focuses on the field of immune sequencing, offering products including immunoSEQ and clonoSEQ, as well as diagnostic tools such as T-Detect COVID, serving research, clinical diagnostics, and drug development applications. Its flagship product, clonoSEQ, is primarily used to detect and monitor minimal residual disease (MRD) in cancer patients. The company generates revenue through the sale of diagnostic tests, the provision of research services, and strategic collaborations in immune-driven medicine. Its key customers include life sciences researchers, clinicians, pharmaceutical companies, and vaccine developers. The company’s strategy is built on proprietary immune sequencing technology and deep data accumulation, aiming to drive innovation in clinical diagnostics and research.
Notably, the company’s stock price had shown strong performance prior to these transactions. As of the day before Lo’s first transaction, Adaptive Biotechnologies’ stock had delivered a total return of over 105% over the previous year; prior to Rubinstein’s transaction, the stock had also risen by more than 70% over the past year. In its financial report released in February 2026, the company reported full-year 2025 revenue of $277 million, a year-over-year increase of 55%, with its core MRD business contributing the primary growth momentum. The company achieved positive adjusted EBITDA and positive cash flow. Testing volumes for clonoSEQ grew significantly, and partnerships with large pharmaceutical companies further expanded its data advantages. Although the company is not yet profitable under generally accepted accounting principles (GAAP), its full-year loss narrowed substantially to approximately $59.5 million.
Analysts suggest that against the backdrop of a significant stock price increase, executives reducing holdings for tax planning or asset allocation purposes is a normal practice. Rubinstein continues to hold a substantial number of stock options, and Lo retains a significant amount of direct holdings, reflecting management’s continued commitment to the company’s future.
